• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Sweden·Healthcare·NEWBRY.ST
Share

Newbury Pharmaceuticals AB Stocks

SEK 2.38Last Updated 18.09.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

SEK 6.68M

SEK 2.38
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Newbury Pharmaceuticals AB (publ), a hybrid pharmaceutical enterprise, serves both the Swedish and wider Scandinavian markets. Formed in 2020 and headquartered in Lund, Sweden, the company provides a variety of therapeutic solutions, with a strong emphasis on oncology, rare diseases, and neurology, in addition to other treatment categories.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.09.2026 23:48

Meta shares are having their best month in 13 years, with the price at its highest level since October. Is it too late to buy?

21.09.2026 23:31

A $30 Trillion Market and the Risk of an Apocalypse: How Much Could Anthropic Be Worth? — An FT Analysis

21.09.2026 23:15

Amazon has blocked Meta's AI agent on its marketplace. What's the issue?

21.09.2026 22:41

The price of Brent crude oil fell below $100 per barrel

21.09.2026 20:59

Laptop with On-Device AI: Google Announces Release Date and Prices for the First Googlebooks

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026